Synthesis of Quinazoline Analogues with Differential Activity for HER2‐overexpressing Breast Cancer Cells

Publisher： John Wiley & Sons Inc

E-ISSN： 1229-5949|36|7|1933-1935

ISSN： 1229-5949

Source： BULLETIN OF THE KOREAN CHEMICAL SOCIETY (ELECTRONIC), Vol.36, Iss.7, 2015-07, pp. : 1933-1935

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 38-45

Karger

Access to resources Recommend Favorite

Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 582-586

Karger

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite

Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line

By              

International Journal of Molecular Medicine, Vol. 28, Iss. 6, 2011-01 ,pp. : 985-991

Spandidos Publications

Access to resources Recommend Favorite

HER2: The Neu Prognostic Marker for Breast Cancer

By Tsongalis Gregory J.   Ricci Jr. Andrew  

Critical Reviews in Clinical Laboratory Sciences, Vol. 38, Iss. 2, 1998-03 ,pp. : 167-182

Informa Healthcare

Access to resources Recommend Favorite